Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2014 Nov;12(11):1407-17. doi: 10.1586/14787210.2014.959496. Epub 2014 Sep 10.

Treatment options for second-stage gambiense human African trypanosomiasis.

Author information

1
Geneva University Hospitals, Geneva, Switzerland.

Abstract

Treatment of second-stage gambiense human African trypanosomiasis relied on toxic arsenic-based derivatives for over 50 years. The availability and subsequent use of eflornithine, initially in monotherapy and more recently in combination with nifurtimox (NECT), has drastically improved the prognosis of treated patients. However, NECT logistic and nursing requirements remain obstacles to its deployment and use in peripheral health structures in rural sub-Saharan Africa. Two oral compounds, fexinidazole and SCYX-7158, are currently in clinical development. The main scope of this article is to discuss the potential impact of new oral therapies to improve diagnosis-treatment algorithms and patients' access to treatment, and to contribute to reach the objectives of the recently launched gambiense human African trypanosomiasis elimination program.

KEYWORDS:

SCYX-7158; eflornithine; fexinidazole; gambiense; human African trypanosomiasis; melarsoprol; nifurtimox; oxaborole; second stage; sleeping sickness

PMID:
25204360
PMCID:
PMC4743611
DOI:
10.1586/14787210.2014.959496
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center